DXCM: We Are Removing Dexcom from Investing Ideas

12/12/19 03:43PM EST

A quick note from Hedgeye CEO Keith McCullough:

Given DXCM’s correction in the last few weeks towards immediate-term TRADE #oversold, I think the prudent risk management decision is to stop us out of the idea, for now, and revisit as Tom Tobin collects more real-time data.

***No change to Healthcare analyst Tom Tobin's fundamental short thesis on Dexcom.

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.